Genoray Co., Ltd.

As of June 30, 2026, Genoray Co., Ltd. carries a market capitalization of 43.10B, placing it among publicly traded companies globally. Its enterprise value stands at 58.76B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Genoray Co., Ltd. has 12.73M shares outstanding.

As of June 30, 2026, Genoray Co., Ltd. trades at a trailing price-to-earnings ratio of 16.21. The price-to-sales ratio is 0.39, and the price-to-book ratio stands at 0.53.

As of June 30, 2026, Genoray Co., Ltd. trades at an EV/EBITDA multiple of 8.39 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.54 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 58.76B versus a market cap of 43.10B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Genoray Co., Ltd. maintains a current ratio of 1.88, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 44.86, indicating elevated leverage, while an interest coverage ratio of 6.14 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Genoray Co., Ltd. posted a return on equity (ROE) of 3.23, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 1.97, measuring how efficiently the asset base is converted into earnings. The company generates approximately 301.34M in revenue per employee across its workforce of 358.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.30 indicates how many times Genoray Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Genoray Co., Ltd. recorded an income tax benefit of -1.68B rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 865.61M, leaving 2.61B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Genoray Co., Ltd.'s stock has declined approximately 38.92% over the past 52 weeks. The 50-day moving average sits at 3,319.10, while the 200-day moving average is 3,887.38.

Over the twelve months ended June 30, 2026, Genoray Co., Ltd. generated 107.88B in revenue and converted that into 2.61B in net income, yielding earnings per share of 203.87. EBITDA reached 7.00B, while operating income came in at -1.61B.

As of June 30, 2026, Genoray Co., Ltd. holds 19.94B in cash and equivalents against 36.36B in total debt, resulting in a net debt position of 12.18B. Total book value stands at 81.81B, with working capital of 41.21B providing operational flexibility.

Genoray Co., Ltd. produced 9.08B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -874.79M in capital expenditures, free cash flow totaled 8.20B - equivalent to 657.25 per share.

Over the twelve months ended June 30, 2026, Genoray Co., Ltd. posted a gross margin of 39.76, reflecting its pricing power and cost economics. The operating margin of -1.49 and net profit margin of 2.42 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Genoray Co., Ltd. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 19.42, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 5.61, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Genoray Co., Ltd. shareholders.

Genoray Co., Ltd.'s most recent stock split took place on February 21, 2020 with a 1:3 split ratio.

As of June 30, 2026, Genoray Co., Ltd. has an Altman Z-Score of 2.42, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.